Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

BioGaia, Audiocast, Q1'26

By Inderes5/7/2026, 7:30 AM
BioGaia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Theresa Agnew
00:01 - 11:07

Hi, this is Theresa Agnew, CEO of BioGaia, and we are here to present our Q1 2026 results. In terms of the highlights, we have growth excluding currency effects of 15%. Our EBIT margin for the quarter is 27%. And overall, our free cash flow is 67 million SEK. Our net sales reached 373 million SEK. And as I said, organic growth of 15%. 2% growth when you include currency effects. Our Asia Pacific region increased by 6%, excluding currency effects. In the Americas, we increased by 12%, excluding currency effects. And for Europe, Middle East, and Africa, we increased by 24%, excluding currency effects. Our operating profit for the quarter was around 101 million SEK, which is 4% growth. And our EBIT margin, as I said, was 27%, compared to 27% for the same quarter last year. To remind you of our company strategy. We have three strategic pillars. Grow the Core, where we focus on growing our core health areas. Gut health, of which colic is a part. Oral health and immune health. Our second strategic pillar is what we call expansion through direct markets. So focusing on growing our current 12 direct markets and focusing our marketing and selling and investment activities in those markets to drive growth ahead of market. And our third strategic pillar is what we call breakthrough innovation, where we work on new products that are in new areas. So new market creation opportunities for probiotics. And our foundations are, of course, our people and our culture investing for profitable growth, using digital as an enabler of the business, both in how we go to market in our omnichannel approach, as well as how we digitize internally to make us more productive and efficient, driven by science, which has been a foundation for us for over 35 years, and sustainable solutions. How are we delivering on our strategy in terms of grow the core for the quarter? We are driving growth in both the pediatric and adult segments. We are investing, as I said, in marketing and selling activities to drive strong double-digit growth in direct markets. We're continuing the rollout of new products. We launched a new product, BioGaia Gastrus Pure Action, in Finland originally in October 2024, and now we have rolled it out to approximately 12 markets, and it is now the third highest growth contributor to our overall business in terms of million SEK for a second quarter in a row. It was our third largest growth contributor in Q4 and again now in Q1 2026. And we are also rolling out a new product, BioGaia Prodentis Fresh Breath, which launched last year in Q3. And we continue to roll that out into more markets. In terms of expansion through direct markets, we launched Germany and Austria earlier in Q1, and that is doing really well with strong growth ahead of our plan. France and Canada actually had record sales in Q1. So both of those direct markets are doing very strongly. And then US continues in Q1 with its strong double-digit growth trend. So direct markets performing extremely well in the Breakthrough Innovation area, we have our BioGaia New Sciences Focus, which is on skin health. And we continue to roll out our probiotic ointment to more and more countries around the world. And we have some exciting news to announce a new product launch in our pediatrics area. This is our next-generation patented probiotic baby drops, which is, as you know, a dual-strain product. This is our next generation patented probiotic baby drops, which I think as you know, this is a dual strain product. So this contains our original Protectis strain, which is DSM 17938. And a new patented strain, which we call BGR 46. Our current Protectis drops will remain available in the market. So this will be an additional product launch which will round out our premium portfolio in terms of baby drops. We just completed a clinical study where we achieved positive results both in efficacy and safety. So we will be writing a manuscript and submitting this for publication. So with this product, we get the benefit of additive probiotic effects. So it's supported by numerous preclinical studies that have been published, such as the survival and activity in a bile-rich environment, which is very important for bacteria to survive. The BGR 46 also increases melatonin induction in the intestinal cells. So this is a really positive differentiator in this strain. This new strain also has higher production levels of anti-inflammatory compounds such as adenosine, and this new strain is even better adapted to the infant gut in a milk-rich environment. So there are a number of things that we've studied preclinically about this new strain, BGR 46, which provide additive probiotic effects. But as I said, this is a new product that will be available in addition to our original BioGaia Protectis drops. Our first launch is actually this week in the UK. And then we will follow with additional rollouts by market over this year and into next year. So, very exciting news for us in terms of a new product launch. Our next-generation probiotic drops, in addition to other launches, were introduced in the quarter. As always, alongside our existing product portfolio, we talk about other launches as we expand into new countries. So, just a couple of examples. We launched our Prodentis Fresh Breath lozenges in Sweden and Germany. Of course, we launched some new products in the quarter as we started our direct market presence in the quarter. Also, Prodentis Fresh Breath lozenges launched in the UK and Finland in this quarter. Malaysia launched our BioGaia Skincare Probiotic ointment. So, a number of other product launches occurred within the quarter, alongside some of the other key events. We had quite a bit of news in the quarter. On February 3rd, we announced that our fourth quarter would exceed market expectations. In February, we signed a renewed distribution agreement with a long-standing partner, Ewopharma. And they cover Central and Eastern Europe as well as Switzerland. For us, on March 17th, we also announced exercising the option to acquire the remaining 20% of the shares in Nutraceutics, which is our company in the United States. On March 20th, we announced an exciting clinical study publication. It's a ten-year follow-up study from when infants were given our Protectis drops. And we saw that there was a markedly lower prevalence of functional abdominal pain in these children after they had received our drops in the first three months of life. And then finally, at the end of April, we also published new scientific findings around our patented LongevityGuard technology, which is our desiccant strip that goes into our drops products as well as our probiotic ointment to improve the stability and extend the shelf life of our probiotics to 24 months. So a lot of interesting, exciting news that we had during the quarter in terms of growth as we look at it across our segments. You can see the past growth by quarter. So in pediatrics for Q1, we grew by 13% excluding currency effects. And in the adult segment we grew by 18% excluding currency effects. In pediatrics, we saw very high sales in the US and also France in the quarter. And in adults, we saw very high sales in EMEA, Asia Pacific, and we saw strong growth in South Africa as well as Japan. In addition, looking at our Pediatrics segment for the quarter, we grew 13% excluding currency effects. Adult health, we grew 18% excluding currency effects. So strong growth for both segments. And currently for the quarter, 73% of our sales are in the pediatric segment. In terms of our regional sales, I highlighted this in the beginning. EMEA grew 24% excluding currency effects. Asia Pacific grew 6% and Americas grew 12%. With EMEA, we saw strong growth in both the Pediatrics and Adult segments. In Asia Pacific, we saw strong growth in Japan and Australia. Our direct markets in Asia Pacific also saw strong growth. Sales for the quarter were negatively impacted by some quarterly variations that we saw for China between Q4 and Q1 and in the Americas. As I said, we saw 12% growth excluding currency effects, with strong growth in the US and Canada and growth in the quarter also strong for both the Pediatrics segment and the Adult Health segment. Now I will turn it over to Alex to go through the financials in some more detail.

Alexander Kotsinas
11:07 - 14:31

Thank you, Teresa. So to summarize, we had a sales increase in constant currency of 2%, to 373 million SEK from 366 million SEK. We had a gross profit margin decrease of 1 percentage point, from 73% to 72%. We had an EBIT increase of 4% and a margin of 27%. If we look at the sales, as we heard, we had an organic increase of 15%. However, we had very strong negative currency effects of 13%, and the net increase then was 2%. The gross margin for the quarter was 72% versus 73% in the same quarter last year. We had a slightly lower margin for both pediatrics and adult. The main reason for the lower margin is the strengthening Swedish Crown versus mainly the dollar that is affecting the gross margin. Our operating expenses amounted to 166 million compared to 171 million in the same quarter last year, representing a 3% decrease. This is mainly due to the other opex line, where we have a negative cost of 6 million versus the cost of 24 million in the same quarter last year. And if you exclude that effect, we have an increased sales and marketing cost of 17%. And the main reason for the increased sales and marketing cost is that we are having this increase in sales in different markets, and therefore we have higher costs. We are investing in our growth in terms of R&D. We also have a slight increase of 13%. And Administration expenses also increased by 24%. It's partly due to some periodization of some costs. If we look at then our P&L like we heard, we had sales of 373 million and opex 166, and thereby an EBIT of 101 million versus 97 million in the same quarter last year, an increase of 4% and a profit after tax of 79 million versus 80 million, which is a slight decrease of 1% and earnings per share of 0.78, which is a slight decrease of 1%. If we go over to the cash flow. We have a cash flow from operating activities before changes in working capital of 66 million. And we have a positive change in working capital of 5 million, leading to a cash flow from operating activities of 70 million versus 36 million in the same quarter last year. We have a very low cash flow from investing activities of only 1 million. It was also low in the same quarter last year. And the cash flow from financing of minus 2 million SEK, leading to a cash flow for the period of 67 million versus 33 million in the same quarter last year, and cash at the end of the period of 871 million versus 1.25 billion last year. So with that, I hand over to Teresa.

Theresa Agnew
14:31 - 17:27

Great. So in conclusion, as we said, our first quarter showed growth excluding currency effects of 15%. We are happy to report that both our pediatric segment and our adult segment grew double digits. And as we said, this increase is primarily driven by our BioGaia Protectis drops, our BioGaia Prodentis Fresh Breath, and our BioGaia Gastrus Pure Action. One of our new launches from 2020 for Europe, Middle East, Africa, is regaining momentum in some of the key markets that underwent a period of transition last year as we shifted from a partner-run business to now taking some markets direct. So we are through that period of transition for one of our largest markets, France. So that is really showing in our results. And overall, as we said, in Europe, Middle East, Africa, our sales increased by 24% excluding currency effects. And as I said, France performed well. Germany also performed very well. We just launched in January, and as I said, we are ahead of plan. So both of those markets have contributed strongly to our performance in Europe, Middle East, Africa. As I said, we had strong growth in Australia, Japan, Vietnam. We had some order variability in China in the quarter. And then specifically in Australia, the BioGaia Gastrus product line was a key contributor to the positive development in our sales as well as our BioGaia Protectis drops. And in Japan, we saw increased sales through not only our own e-commerce channels, but also very strong collaboration with local wholesalers for distribution in bricks and mortar retail. The Americas overall delivered strong performance with 12% growth when you exclude currencies. Both of our direct markets, Canada and the US, had strong double-digit growth. Strong sales of adult products such as BioGaia Protectis Plus as well as BioGaia Gastrus Pure Action, and then also strong double digit growth of BioGaia Protectis drops in the US. And as we said, our operating margin was 27% for the quarter. And as a company, we remain focused on driving this sustainable growth. We leverage our scientific foundation, as you heard from us, a number of different scientific publications in the quarter. Also in the second quarter, a launch of a new product that has a strong scientific foundation with all of our preclinical studies. And now a new clinical study. And we are expanding our presence in our key markets, and we're increasing our brand visibility with a strong focus on our marketing and selling activities. So I open it up now for any questions.

Operator
17:28 - 17:45

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Matthias from SEB. Please go ahead.

Matthias
17:48 - 18:41

Good morning. Thanks for taking my questions. My first question relates to the next generation patented probiotic drops that the press release mentioned this morning. So a few questions there. So there are additive effects of the combination, as observed preclinically. But they've also been positively studied, as you mentioned, and shown to be safe in the randomized, double-blinded clinical study. So just to clarify exactly what that means. And also to that, do you see the prior colic drops product being cannibalized? Now, when you launch in three markets, in what year does the patent expire? Sorry for many questions, but those were the thoughts I had.

Theresa Agnew
18:42 - 19:46

Yes, thank you for that. So, for the next-generation BioGaia Protectis Plus product, we have a clinical study. So as we said, a double blind, randomized, placebo controlled study. So we are not talking specifically about the results of that study yet because we are submitting it for publication. But when we say a positive study, meaning in efficacy as well as safety, this product will also be premium to the existing product. So around a 15% price premium. We do expect some cannibalization over time. It will take a while for the new product to be launched in numerous markets. Because it is a new strain, and in many markets it requires specific registrations for a new strain. So this will happen over time, but we do eventually expect some cannibalization, but it will be premium priced.

Matthias
19:50 - 19:52

Okay. And, the year for which the patent...

Theresa Agnew
19:52 - 19:57

Oh, I'm sorry. So it's a full patent of 20 years.

Matthias
20:00 - 20:06

Okay. And can you share your plans for launching it in the US?

Theresa Agnew
20:07 - 20:23

For the US. We need to get what's called GRAS approval for a new strain. So that process is starting. And we can't really predict exactly how long that takes. It depends on the review by the regulatory authorities.

Matthias
20:25 - 20:48

Okay, good. That's good news. And looking forward to read a publication later on the Gastrus Pure Action product. So I'm just keen to hear how many markets it has been launched in. And if you foresee major countries with expected rollouts in the coming months. That's the second one.

Theresa Agnew
20:48 - 21:36

So it has been launched thus far in 12 countries. So there will be more markets that will be coming through. We don't specifically announce which markets when because it all depends on registrations and regulatory requirements. We have launched it though already in some of our bigger markets, such as the US and Canada. And we have a pending launch for it in some of the European markets. So we will be launching it upcoming in Italy for instance. So it hasn't launched there yet. And then in Asia, it has launched in a number of our larger markets, but mainly through online channels.

Matthias
21:39 - 21:59

That's very clear. Thank you. Then I was keen to hear the status on Eastern Europe. If that is recovered in line with your expectations. Also, regarding the new agreement with Ewopharma, is that similar to the prior one, or are there any changes there?

Theresa Agnew
21:59 - 22:12

Well, no major changes. It's very similar to the prior one. When we do these new contracts, we then agree on minimum quantities in terms of volume. So no major changes.

Matthias
22:15 - 22:16

Okay. Thank you very much.

Operator
22:20 - 22:24

The next question comes from Matthias Haggblom from Handelsbanken. Please go ahead.

Matthias Haggblom
22:27 - 23:22

Thanks so much for taking my question. I have two, please. So firstly, on the margin expansion, I think the messaging into 2026 has been around operating leverage and margin expansion. And if you adjust for other operating income, which was mainly FX, it was positive this year and a large negative last year. We're looking at an EBIT margin contraction and not flat year over year, which is the reported one. So was this quarter an outlier, or have you to an extent, walked away from the previous commitment of expanding margins for 2026? And then secondly, again on the new strain, and perhaps this morning, you highlight a number of characteristics that make Protectis Plus a better product. But for parents with infants with colic, crying time is what matters. So on more hard endpoints, can you talk about how the product differs, if at all, versus the original Protectis? Thanks so much.

Alexander Kotsinas
23:24 - 23:51

So I can start with the margin. So we're still committed to improve our margin during this year. That is definitely our plan. It should happen in the coming quarters. And that's a combination of cost control and also increased sales that will improve our margin percentage. Then for the new strain, maybe Theresa can give some comments.

Theresa Agnew
23:51 - 24:40

Yes. So we did see in our clinical study a positive reduction in crying time. So overall crying time, as well as what we call unconsolable crying time. So that was significant. We did not compare the product specifically to Protectis because we use gold standard protocols to do double-blinded, placebo-controlled trials. So, the percentages of the reduction in crying time were higher than we've seen with the original Protectis, but we can't share the specific details because we want to get it published. And we did not compare the two products specifically.

Matthias Haggblom
24:42 - 24:43

Thanks so much.

Operator
24:48 - 24:53

The next question comes from Christopher Lilleberg from NB Carnegie. Please go ahead.

Christopher Lilleberg
24:56 - 25:17

Hi. Quite a number of questions. I might take a few and then get back in the queue, but I'll start first. Could you describe how you view the underlying growth momentum, given that you were growing a strong 15% organically here? Despite that, there should have been negative phasing effects between Q1 and Q4.

Theresa Agnew
25:18 - 25:46

Yes. We've seen strong growth in Q1. This has been driven very strongly by our direct markets. So our direct markets are doing very well overall, in terms of the performance in each market versus the competition, growing ahead of the overall category. So we feel really good about the momentum we are seeing in our direct markets.

Christopher Lilleberg
25:49 - 25:52

And how a large part of sales is in direct markets.

Theresa Agnew
25:52 - 26:23

Now, for the quarter, it was actually 50-50. So 50% direct markets and 50% partner markets. But we also had some order variability. So some of our larger partners like China and Italy had some order variability. So we don't anticipate the 50/50 split will continue. But we will be getting to 5050 overall, as we've said before, in the next year to year and a half.

Christopher Lilleberg
26:26 - 26:43

Okay. Great. Thanks. And the strong growth in EMEA here, which I think is, is primarily driven by Europe. How sustainable do you see this, given that this region hasn't been growing for the last three years, more or less.

Theresa Agnew
26:45 - 27:25

I think it's overall sustainable for this year in terms of double-digit growth. We have strong performance, as we said in France. So now that we've worked through the higher inventory levels with our partners and in our own direct market, we also have a new agreement that has started with a partner in Turkey. So Abbott Turkey. So we anticipate that will show some nice growth in the back half of the year. So overall, we feel we will continue with some strong double-digit growth in EMEA.

Christopher Lilleberg
27:28 - 27:32

And do you think it's sustainable also 2027 and forward.

Theresa Agnew
27:33 - 28:05

Yes, I do think it is sustainable. Because we have this presence of our direct markets that are large markets overall in the region. And also, other markets that are partner markets are doing well. In addition, such as we talked about South Africa, hopefully we look at Turkey where we've had a lower Q1 and first half of this year for Turkey. So we should see some nice growth next year.

Christopher Lilleberg
28:06 - 28:41

Okay. I'll do two more questions. I hope that's okay. Following up on a previous question. Selling costs here or operating costs in the quarter. And I think you said that you will have a combination of cost control and higher sales driving better margin for the year. But when you say cost control, could we expect selling costs to become lower for the remainder of the year, or is this the level where it should stay at?

Alexander Kotsinas
28:43 - 29:26

Yeah, we won't really provide that level of detail on guidance. But overall, like I said, we will keep our costs under control. I think we have said previously that we will, our ambition is to keep them fairly flat compared to the last year, overall. And then we will have an increase in sales, like we have now in the first quarter. So, it will vary a bit between the quarters. We have some natural seasonal variations and so on between the quarters, for example. But overall for the year, the ambition is basically for the total cost to be fairly flat, excluding then maybe some currency effects that could go a bit in different ways.

Christopher Lilleberg
29:28 - 29:36

Yeah. So that's important. So when you say flat operating costs that adjust for the FX in the other line.

Alexander Kotsinas
29:38 - 29:45

Uh, yeah. Assuming that there are no major FX effects going up or down, so to speak. So excluding. Yeah.

Christopher Lilleberg
29:45 - 30:10

Okay. And then my final one on Protectis. If you could confirm the price premium, was it 15% or 1.5%? 1.5%? And also, that's correct. Okay. And then, when it comes to the clinical data concerning crying time, is it possible to confirm that? That was statistically significantly lower.

Theresa Agnew
30:11 - 30:15

Yes, yes, we can say that it is statistically significant.

Christopher Lilleberg
30:17 - 30:18

Great. Thank you very much.

Operator
30:21 - 30:33

As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Matthias Haggblom from Handelsbanken. Please go ahead.

Matthias Haggblom
30:36 - 31:12

Thanks so much. I just had a follow-up question on the gross margin and the impact of the Swedish krona versus the dollar. Was that to explain the gross margin contraction? But this trend started already in Q2 last year, and I can't recall this effect. This relationship has been brought up before. Often when we've had individual quarters with weak gross margin, it's often been historically related to product mix and campaigns or certain mix effects. So, is there something I missed here, or how should I think about that for the next couple of quarters then?

Alexander Kotsinas
31:13 - 31:30

No. That's correct. It's partly a mixed effect here also in the quarter for sure. But it is the FX effect, which as you say, of course we have had that effect previously as well, but it's a bit stronger in this quarter actually. And then we still have mixed effects in the quarter affecting things here.

Matthias Haggblom
31:34 - 31:37

Okay, good. That's all from me. Thanks so much.

Operator
31:38 - 31:42

The next question comes from Matthias from Seb. Please go ahead.

Matthias
31:45 - 32:11

Thanks. A few more questions. So one is here a bit more about Germany. In this letter you say it contributed positively, which sounds quite good if it contributes to organic growth already now. So just make sure I catch that correctly. And also, is it a fair assumption that Germany sales were fairly limited from Q2 through Q4 in 2025?

Theresa Agnew
32:12 - 32:32

Yes, that is correct. So yes, it is contributing already in Q1 organically. So that's very positive for us, as we grow that business in Germany. And then you're correct with your other statement as well, that we had lower orders from our partner from Q2 to Q4.

Matthias
32:35 - 32:47

Good. Thank you. And then in the US, the growth in the US, specifically in local currencies, was that 15, 20 or 30% or can you comment on that?

Unknown 2
32:48 - 32:51

We will share the US.

Theresa Agnew
32:52 - 33:00

At the end of the year, once a year, we don't specifically comment on it, but we can say that it is double-digit growth.

Matthias
33:04 - 33:23

Okay. Thank you. And then, R&D expenses quite low in the quarter. Should we expect the seasonally higher R&D costs to come through in Q2, or will it be lower now as this study is more or less done?

Theresa Agnew
33:25 - 34:02

One thing is, we are conducting what we call bridging clinical studies, where we look at our new patented strains and will be bringing out further products. We will be spending in clinicals. So we will be looking at different indications for our BG R46 Protectis Plus combination as well as other strains. So we will continue with clinical costs. But it is true. Our main study is completed. But then we have other studies also that are ongoing. I don't know if you want to add something more.

Alexander Kotsinas
34:02 - 34:18

And then there will be some variations between the quarters, depending on those clinical studies when they start or end or include subjects, etc. . So it is a bit volatile, so to speak, that cost. But it will probably increase going forward.

Matthias
34:20 - 34:32

Good. And then the last one should be fairly quick. So APAC with the 6% growth. If the phasing effect were not present, would the growth be more in line with past years' performance for APAC?

Theresa Agnew
34:33 - 34:40

Yes. Overall, without that order variability, it would be more in line with previous performance.

Matthias
34:41 - 34:43

Okay. Thank you very much.

Operator
34:46 - 34:52

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Theresa Agnew
34:53 - 35:02

Thank you for your time and listening to our Q1 2026 results. Thank you for your questions, and we will end the conference now.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…